Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-κB signaling

Area of Science:

• Natural product chemistry
• Gastroenterology
• Oncology

Background:

• Inflammatory bowel disease (IBD) and colitis-associated cancer (CAC) pose significant health challenges.
• Apigenin, a flavonoid, exhibits anti-inflammatory, antioxidant, and anticancer properties.
• The therapeutic potential of apigenin in IBD and CAC requires further investigation.

Purpose of the Study:

• To investigate the effects of apigenin on ulcerative colitis, a type of IBD, and CAC.
• To elucidate the molecular mechanisms underlying apigenin's action in these conditions.

Main Methods:

• Administration of apigenin to animal models of IBD and CAC.
• Assessment of inflammatory markers, including myeloperoxidase (MPO) and cytokine levels.
• Evaluation of cyclooxygenase-2 (COX-2) expression and inflammatory cell infiltration.
• Analysis of NF-κB and STAT3 signaling pathway activation in vitro and in vivo.

Main Results:

• Apigenin significantly inhibited ulcerative colitis and CAC.
• Apigenin treatment reduced MPO, inflammatory cytokine, and COX-2 levels.
• Apigenin attenuated inflammatory cell infiltration in colon tissues.
• Apigenin suppressed NF-κB and STAT3 activity, both in vitro and in vivo.

Conclusions:

• Apigenin demonstrates potent anti-inflammatory and anticancer effects in the context of IBD and CAC.
• Apigenin inhibits inflammation and inflammation-induced carcinogenesis by suppressing the STAT3-NF-κB signaling pathway.
• Apigenin represents a promising therapeutic agent for managing IBD and preventing CAC.